Data / Drug companies / Bacitracin zinc, neomycin sulfate , polymyxin b sulfate.
Bacitracin zinc, neomycin sulfate , polymyxin b sulfate.: 5 companies and 10 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bacitracin zinc, neomycin sulfate , polymyxin b sulfate. is listed in the FDA National Drug Code Directory by 5 companies, with 10 products in commercial distribution. 0 of the products (0.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are ointment, and the newest product started marketing on January 27, 2026.
The request: Get every company that lists bacitracin zinc, neomycin sulfate , polymyxin b sulfate. in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 5
- Products
- 10
- Generic (ANDA) products
- 0 (0.0%)
- Application numbers
- 1
- Routes
- Topical
- Brand names
- Triple Antibiotic, QC Triple Antibiotic
- openFDA record search
- api.fda.gov
Companies that list bacitracin zinc, neomycin sulfate , polymyxin b sulfate.
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| ProStat First Aid | 4 | ointment | Over the counter monograph drugs | January 27, 2026 |
| Trifecta Pharmaceuticals USA LLC | 3 | ointment | Over the counter monograph drugs | October 14, 2025 |
| Chain Drug Marketing Association, Inc. | 1 | ointment | Over the counter monograph drugs | March 15, 2024 |
| Front Pharmaceutical PLC | 1 | ointment | Over the counter monograph drugs | April 8, 2025 |
| Geri-Care Pharmaceuticals, Corp | 1 | ointment | Over the counter monograph drugs | April 1, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Ointment | 10 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 10 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Aminoglycoside Antibacterial | 10 |
| Polymyxin-class Antibacterial | 10 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.